TransMedics Group, Inc.
TMDXNasdaq
$73.98
↓ -2.7%Jul 17 close · end-of-day
Price
1Y↓ -34.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.7B
Enterprise Value
$2.7B
P/E
16.9
P/S
4.2
P/B
5.4
EV/EBITDA
21.1
PEG
—
FCF Yield
5.7%
Dividend Yield
—
Revenue (TTM)
$635.9M
Net Income (TTM)
$171.9M
Free Cash Flow (TTM)
$151.4M
Gross Margin
59.1%
Operating Margin
14.8%
Net Margin
27.0%
ROE
34.8%
ROIC
18.6%
Debt / Equity
0.0
Net Cash
-$15.0M
Return 1Y
-34.3%
Company profile
TransMedics Group, Inc. engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system. OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation.
- CEO
- Waleed H. Hassanein
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 210
- Headquarters
- Massachusetts
- Website
- transmedics.com
Earnings
TMDX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$173.9M↑ +21.2%
Diluted EPS$0.20↓ -71.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $25.6M | $30.3M | $93.5M | $241.6M | $441.5M | $605.5M |
| Gross profit | $16.6M | $21.2M | $65.3M | $154.1M | $262.1M | $362.8M |
| Operating income | -$26.4M | -$39.4M | -$31.4M | -$28.7M | $37.5M | $108.6M |
| Net income | -$28.7M | -$44.2M | -$36.2M | -$25.0M | $35.5M | $190.3M |
| Diluted EPS | -$1.16 | -$1.60 | -$1.23 | -$0.77 | $1.01 | $4.87 |
| Operating cash flow | -$30.3M | -$28.9M | -$45.8M | -$13.0M | $48.8M | $192.8M |
| Free cash flow | -$30.7M | -$32.4M | -$57.7M | -$164.9M | -$80.9M | $133.6M |
| Gross margin | 64.9% | 69.9% | 69.8% | 63.8% | 59.4% | 59.9% |
| Operating margin | -102.9% | -130.3% | -33.6% | -11.9% | 8.5% | 17.9% |
| Net margin | -112.1% | -146.1% | -38.7% | -10.3% | 8.0% | 31.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $114.3M | $108.8M | $121.6M | $143.5M | $157.4M | $143.8M | $160.8M | $173.9M |
| Gross profit | $69.3M | $60.8M | $72.0M | $88.2M | $96.6M | $84.6M | $93.4M | $101.2M |
| Operating income | $12.5M | $3.9M | $8.6M | $27.4M | $36.6M | $23.3M | $21.3M | $13.3M |
| Net income | $12.2M | $4.2M | $6.9M | $25.7M | $34.9M | $24.3M | $105.4M | $7.3M |
| Diluted EPS | $0.35 | $0.12 | $0.19 | $0.70 | $0.92 | $0.66 | $2.59 | $0.20 |
| Operating cash flow | $25.7M | $6.9M | $19.7M | -$2.9M | $91.6M | $69.6M | $34.5M | $24.5M |
| Free cash flow | $2.0M | -$41.3M | $6.1M | -$29.9M | $82.5M | $61.9M | $19.0M | -$12.1M |
| Gross margin | 60.6% | 55.9% | 59.2% | 61.5% | 61.4% | 58.8% | 58.1% | 58.2% |
| Operating margin | 10.9% | 3.6% | 7.1% | 19.1% | 23.2% | 16.2% | 13.2% | 7.6% |
| Net margin | 10.7% | 3.9% | 5.7% | 17.9% | 22.2% | 16.9% | 65.6% | 4.2% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.